Comparative Pharmacology

Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 5MEQ K versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K) vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

Electrolyte

Category A/B

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Electrolyte

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Dextrose 5% provides free water and calories, promoting glucose metabolism and cellular energy production; sodium chloride 0.2% provides sodium and chloride ions for maintenance of extracellular fluid volume and osmolality; potassium chloride provides potassium ions essential for nerve conduction, muscle contraction, and acid-base balance.

Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.

Clinical Dosing

Intravenous infusion, administered at a rate of 100-125 mL/hour in adults, adjusting based on fluid and electrolyte status. Typically provides 5 g dextrose, 34 mEq sodium, 34 mEq chloride, and 5 mEq potassium per liter.

1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).

Direct Interaction